B
Bull
Bull · 25%NVS
$136.39
Scenario price
$156.820
+3.074 (+1.96%)At close
Loading chart…
- High
- 156.985
- Open
- 154.150
- VWAP
- 155.98
- Volume
- 3.73M
- Mkt Cap
- 217.41B
- Low
- 154.130
- Amount
- 582.48M
- EV/EBITDA, TTM
- 12.36
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
AI analysis of Novartis AG (NVS)
HoldNovartis AG is currently not a strong buy due to recent clinical trial setbacks and mixed analyst ratings. The current price is $151.12, with an RSI of 54.42 indicating neutral momentum. The forward P/E ratio is 14.71, suggesting potential undervaluation, but the recent negative catalysts, including trial discontinuations, raise concerns about future growth.
Analyst Ratings (3)
-18.54% Downside
Hold
1 Buy
2 Hold
0 Sell
Current: 156.82
Low
112.00
Average
127.75
High
143.00
Morgan Stanley
Overweight
$156
2026-10-06
Morgan Stanley
2026-10-06
Price Target
$156
Overweight
HSBC
Hold
$136
2026-09-10
HSBC
2026-09-10
Price Target
$136
Hold
HSBC
Hold
$110
2026-09-09
HSBC
2026-09-09
Price Target
$110
Hold
Citi
Buy
$135
2026-09-09
Citi
2026-09-09
Price Target
$135
Buy
Deutsche Bank
Hold
—
2026-09-09
Deutsche Bank
2026-09-09
Price Target
—
Hold
Valuation Metrics
The current forward P/E ratio for Novartis AG (NVS) is 14.14, compared to its 5-year average forward P/E of 13.24.
Alphio AI Price Scenarios for NVS
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding NVS
Events Timeline
News
5.010-27CNBCMicrosoft Offers Voluntary Buyouts to 60,000 Employees Amid AI Efficiency Push
5.010-27NewsfilterMicrosoft Offers Voluntary Buyouts to 60,000 Employees Amid AI Efficiency Push
4.510-26CNBCMarket Confidence Rebuilds as AI Trade Recovers
9.510-24CNBCBiotech Sector Recovery: Moderna Leads the Charge
8.510-23FoolBest Countries to Invest in AI's Future Economy
NVS FAQ — answered by Alphio AI
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Novartis AG is currently not a strong buy due to recent clinical trial setbacks and mixed analyst ratings. The current price is $151.12, with an RSI of 54.42 indicating neutral momentum. The forward P/E ratio is 14.71, suggesting potential undervaluation, but the recent negative catalysts, including trial discontinuations, raise concerns about future growth.
3 analysts cover NVS: 1 rate it Buy, 2 Hold and 0 Sell. The average price target is 127.75.
Community
More ↗No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.